Listed by the USPTO as WEBB, WALTER E
Tech Center 1600 • Art Units: 1600 1612 1658
This examiner grants 46% of resolved cases
WEBB, WALTER E examines in tech center 1600 and art unit 1600. The record covers 1007 resolved cases, with a 46.2% allowance rate and a median of 1215 days to allowance. The 18.9% interview lift is positive, indicating an association between interviews and improved allowance outcomes in the reported matters.
The listed companies are L'Oréal, Colgate-Palmolive Company, and The Procter & Gamble Company. The principal firms are Casimir Jones, S.C., OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and The Marbury Law Group, PLLC. The substantial case base supports using the profile for planning, while the below-majority allowance rate and extended median timeline favor early claim differentiation, fallback positions, and disciplined interview preparation.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18941686 | METHOD OF TREATING TEETH USING AN ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES | Non-Final OA | The Procter & Gamble Company |
| 18886278 | Oral Care Compositions With Anticaries Activity | Non-Final OA | The Procter & Gamble Company |
| 18788266 | Fluoride-Free Anticavity Oral Care Compositions | Non-Final OA | The Procter & Gamble Company |
| 18713364 | METHOD OF PREPARING BIODEGRADABLE MICROCAPSULES BASED ON GELATINE | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18413349 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Final Rejection | ASTRAZENECA AB |
| 18734661 | COSMETIC COMPOSITION INCLUDING AN ALOE-TREATED COLORANT | Final Rejection | L'OREAL |
| 18258011 | DYEING COMPOSITION BASED ON 2-GAMMA-HYDROXYPROPYL-PARA-PHENYLENEDIAMINE AND ON A PHOSPHORIC SURFACTANT | Final Rejection | L'Oreal |
| 18008250 | DYEING AND/OR LIGHTENING COMPOSITION COMPRISING AN ANTHRAQUINONE CATIONIC DIRECT DYE, A FATTY SUBSTANCE, A CHEMICAL OXIDIZING AGENT AND A BASIFYING AGENT AND/OR AN OXIDATION DYE PRECURSOR | Final Rejection | L'Oreal |
| 18293248 | COSMETIC COMPOSITION | Final Rejection | KAO CORPORATION |
| 18643489 | Oral Health Composition Comprising Purified Biosurfactants and/or Their Derivatives | Final Rejection | Locus Solutions IPCo, LLC |
| 17628639 | ANTIMICROBIAL COMPOSITIONS | Non-Final OA | GOJO Industries, Inc. |
| 19044040 | Peroxymonosulfate Whitening Strips | Non-Final OA | Colgate-Palmolive Company |
| 19011108 | Oral Care Compositions and Methods of Use | Non-Final OA | Colgate-Palmolive Company |
| 18808749 | Metal Salt Compositions | Non-Final OA | Colgate-Palmolive Company |
| 18354302 | COMPOSITIONS AND RELATED METHODS | Final Rejection | Colgate-Palmolive Company |
| 18109223 | Oral Care Compositions | Final Rejection | Colgate-Palmolive Company |
| 18006482 | Inhibitors of the Artemin Pathway for Treatment of Cancer | Final Rejection | The University of Chicago |
| 18019634 | 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE FOR TREATING THROMBOCYTHEMIA | Non-Final OA | Constellation Pharmaceuticals, Inc. |
| 18020235 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | Non-Final OA | University of Louisville Research Foundation, Inc. |
| 18651043 | CITRIC ACID AND LACTIC ACID DISINFECTING SOLUTION FOR SOFT POROUS SURFACES | Non-Final OA | The Clorox Company |
| 18005425 | COOLING SENSATION COMPOSITIONS | Final Rejection | GIVAUDAN SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy46.2% of resolved applications examined by Walter E Webb were allowed (1,007 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +18.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Walter E Webb took 1,215 days on average from filing to allowance.
Walter E Webb examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).